ZAHRADNÍKOVÁ, Martina, Ivana IHNATOVÁ, Erika LATTOVÁ, Lukáš UHRÍK, Eliška STUCHLÍKOVÁ, Rudolf NENUTIL, Dalibor VALÍK, Monika NÁLEŽINSKÁ, Josef CHOVANEC, Zbyněk ZDRÁHAL, Bořivoj VOJTĚŠEK, Lenka HERNYCHOVÁ a Miloš NOVOTNÝ. N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer. JOURNAL OF PROTEOMICS. Elsevier, 2021, roč. 230, JAN, s. "103964", 13 s. ISSN 1874-3919. Dostupné z: https://dx.doi.org/10.1016/j.jprot.2020.103964.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer
Autoři ZAHRADNÍKOVÁ, Martina (203 Česká republika), Ivana IHNATOVÁ (703 Slovensko, domácí), Erika LATTOVÁ (703 Slovensko, garant, domácí), Lukáš UHRÍK (703 Slovensko), Eliška STUCHLÍKOVÁ (203 Česká republika), Rudolf NENUTIL (203 Česká republika), Dalibor VALÍK (203 Česká republika), Monika NÁLEŽINSKÁ (203 Česká republika), Josef CHOVANEC (203 Česká republika), Zbyněk ZDRÁHAL (203 Česká republika, domácí), Bořivoj VOJTĚŠEK (203 Česká republika), Lenka HERNYCHOVÁ (203 Česká republika) a Miloš NOVOTNÝ (840 Spojené státy).
Vydání JOURNAL OF PROTEOMICS, Elsevier, 2021, 1874-3919.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 10608 Biochemistry and molecular biology
Stát vydavatele Nizozemské království
Utajení není předmětem státního či obchodního tajemství
WWW fulltext
Impakt faktor Impact factor: 3.855
Kód RIV RIV/00216224:14740/21:00121165
Organizační jednotka Středoevropský technologický institut
Doi http://dx.doi.org/10.1016/j.jprot.2020.103964
UT WoS 000597303500009
Klíčová slova anglicky Ovarian cancer; N-Glycans; MALDI-TOF-MS
Štítky CF PROT, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Marie Šípková, DiS., učo 437722. Změněno: 23. 3. 2022 10:20.
Anotace
A number of studies have reported aberrant glycosylation in connection with malignancy. Our investigation further expands on this topic through the examination of N-glycans, which could be associated with the resistance of advanced stage, high-grade non-mucinous ovarian cancer to platinum/taxane based chemotherapy. We used tissue samples of 83 ovarian cancer patients, randomly divided into two independent cohorts (basic and validation). Both groups involved either cases with/without postoperative tumor residue or the cases determined either resistant or sensitive to this chemotherapy. In the validation cohort, preoperative serum samples were also available. N-glycans released from tumors and sera were permethylated and analyzed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The MS analysis yielded a consecutive detection of 68 (tissue) and 63 (serum) N-glycan spectral signals. Eight of these were found to be differentially abundant in tissues of both independent cohorts including the cases with a postoperative cancer residue. One of these glycans was detected as differentially abundant in sera of the validation cohort. No statistically significant differences in intensities due to the same N-glycans were found in the cases without postoperative macroscopic residues in either the basic or validation cohort. From the biochemical point of view, the statistically significant N-glycans correspond to the structures carrying bisecting (terminal) GlcNAc residue and tetra-antennary structures with sialic acid and/or fucose residues. Among them, six tissue N-glycans could be considered potential markers connected with a resistance to chemotherapy in ovarian cancer patients. The prediction of primary resistance to standard chemotherapy may identify the group of patients suitable for alternative treatment strategies. Significance: Drug resistance has become a major impediment to a successful treatment of patients with advanced ovarian cancer. The glycomic measurements related to cancer are becoming increasingly popular in identification of the key molecules as potential diagnostic and prognostic indicators. Our report deals with identification of differences in N-glycosylation of proteins in tissue and serum samples from the individuals showing sensitivity or resistance to platinum/taxane-based chemotherapy. The detection sensitivity to chemotherapy is vitally important for these patients.
Návaznosti
EF15_003/0000469, projekt VaVNázev: Cetocoen Plus
EF17_050/0008496, projekt VaVNázev: MSCAfellow@MUNI
LM2018121, projekt VaVNázev: Výzkumná infrastruktura RECETOX (Akronym: RECETOX RI)
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, RECETOX RI
LM2018127, projekt VaVNázev: Česká infrastruktura pro integrativní strukturní biologii (Akronym: CIISB)
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Czech Infrastructure for Integrative Structural Biology
VytisknoutZobrazeno: 21. 7. 2024 07:28